QbD Group wins AEFI Award for Best Publication of 2025 for its article on pharmacovigilance in innovative therapies
QbD Group is proud to announce that Almudena del Castillo, Head of Global Vigilance Division and Country Manager Spain, has been honored with the prestigious AEFI Award for Best Publication of 2025. The recognition was presented during a formal ceremony held last April at the historic Palacio de los Duques de Santoña in Madrid, in acknowledgement of her article "Pharmacovigilance in innovative therapies: Regulatory and clinical challenges" (originally published in Spanish as "Farmacovigilancia en terapias innovadoras. Desafíos regulatorios y clínicos").
A landmark recognition for pharmacovigilance excellence
The AEFI Award is one of the most respected recognitions within the Spanish pharmaceutical industry, celebrating outstanding contributions that advance scientific knowledge and clinical practice. Being named Best Publication of 2025 underscores the relevance and impact of QbD Group's expertise in pharmacovigilance and patient safety.
The winning article tackles some of the most pressing regulatory and clinical challenges associated with innovative therapies — including Advanced Therapy Medicinal Products (ATMPs), gene therapies and cell therapies — where pharmacovigilance plays a critical role in safeguarding patient safety throughout the product lifecycle.
By covering complex topics such as long-term follow-up, traceability, risk management plans and the evolving regulatory framework, the publication offers practical insights that benefit professionals across industry, regulatory authorities and academia.
Recognizing leadership and scientific contribution
The award ceremony took place at the historic Palacio de los Duques de Santoña in Madrid, a setting that brought together prominent figures from the pharmaceutical industry, regulatory bodies and academia to celebrate excellence in scientific communication.
Almudena del Castillo's article reflects her extensive experience navigating the complex pharmacovigilance landscape and her ongoing commitment to translating regulatory and clinical complexity into actionable knowledge for the life sciences community.
This recognition reinforces QbD Group's leadership position in the Spanish life sciences market and the company's continued investment in thought leadership, science-driven consultancy and high-impact publications that shape the future of drug safety.
"Receiving the AEFI Award for Best Publication of 2025 is an enormous honor and a recognition of how essential pharmacovigilance has become in the era of innovative therapies. This award belongs to the entire QbD Group team, whose dedication and expertise make it possible to address the regulatory and clinical challenges of bringing new therapies to patients safely."
— Almudena del Castillo, Head of Global Vigilance Division and Country Manager Spain, QbD Group
A milestone for the QbD Group team
This award is a testament to the dedication of QbD Group's pharmacovigilance team and the value the company brings to clients across Europe and beyond. It also reflects QbD Group's commitment to building knowledge that supports the safe and successful development of innovative therapies.
As QbD Group continues to expand its presence in Spain and globally, the company remains committed to advancing pharmacovigilance through innovation, regulatory expertise and scientific leadership — ultimately ensuring the highest standards of patient safety in the era of innovative therapies.